The IL-33/ST2 pathway, inflammation and atherosclerosis: Trigger and target?

Area of Science:

• Cardiovascular Research
• Immunology
• Molecular Biology

Background:

• Atherosclerosis involves inflammatory processes, driving plaque formation and instability.
• The Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial provided evidence supporting the inflammatory hypothesis via IL-1β inhibition.
• Novel therapeutic targets and prognostic biomarkers for atherosclerosis are needed.

Purpose of the Study:

• To explore the role of the Interleukin-33 (IL-33)/suppression of tumorigenesis 2 (ST2) pathway in atherosclerosis.
• To investigate the potential of the IL-33/ST2 pathway as a biomarker and therapeutic target.

Main Methods:

• Review of existing literature on inflammatory mechanisms in atherosclerosis.
• Analysis of the expression and function of IL-33 and ST2 in vascular endothelium.
• Discussion of the implications of soluble ST2 (sST2) as a decoy receptor.

Main Results:

• The IL-33/ST2 pathway is expressed in arterial endothelium, with IL-33/ST2 interaction potentially blunting atherosclerotic immune responses.
• Soluble ST2 (sST2) may counteract these protective effects by acting as a decoy receptor.
• Definitive clinical evidence for the IL-33/ST2 pathway's role in atherosclerosis is currently lacking.

Conclusions:

• The IL-33/ST2 pathway presents a promising area for further investigation in atherosclerosis.
• Future studies should focus on validating IL-33/ST2 pathway elements as markers of plaque burden and predictors of cardiovascular events.
• Exploring therapeutic strategies to enhance IL-33/ST2 signaling could offer clinical benefits for atherosclerosis patients.